The DDI Marker Studies Knowledgebase has been updated in January 2025 and is available in the DIDB Resource Center.
In this update, we have continued identifying substrates, inhibitors, and inducers for CYP enzymes and various transporters. A total of 20 compounds were characterized, including substates of CYP2C9, CYP3A, BCRP, OAT1, and OAT3, inhibitors of CYP2C19, CYP2D6, P-gp, BCRP, and OCT2, and inducers of CYP2C19 and P-gp. No strong perpetrators or sensitive substrates were identified.
To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
